
Mustang Bio MBIO
$ 0.73
-0.91%
Annual report 2025
added 03-19-2026
Mustang Bio Long Term Debt Current 2011-2026 | MBIO
Annual Long Term Debt Current Mustang Bio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 456 K | 520 K | 612 K | 348 K | 278 K | 257 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 612 K | 257 K | 412 K |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
7.93 M | $ 19.44 | -0.46 % | $ 909 M | ||
|
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
410 K | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
Atreca
BCEL
|
3.54 M | - | -11.76 % | $ 5.79 M | ||
|
Protara Therapeutics
TARA
|
1.24 M | $ 5.03 | -3.08 % | $ 215 M | ||
|
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | ||
|
Tarsus Pharmaceuticals
TARS
|
608 K | $ 67.0 | -0.3 % | $ 2.8 B | ||
|
bluebird bio
BLUE
|
21.2 M | - | - | $ 546 M | ||
|
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | ||
|
Theravance Biopharma
TBPH
|
10.9 M | $ 14.9 | -1.91 % | $ 750 M | ||
|
Avid Bioservices
CDMO
|
1.35 M | - | - | $ 789 M | ||
|
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
Autolus Therapeutics plc
AUTL
|
5.05 M | $ 1.2 | -6.97 % | $ 306 M | ||
|
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B | ||
|
Bio-Techne Corporation
TECH
|
14.1 M | $ 51.31 | -2.65 % | $ 8.08 B | ||
|
Tenax Therapeutics
TENX
|
107 K | $ 14.64 | -2.2 % | $ 574 M | ||
|
Cara Therapeutics
CARA
|
1.92 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
2.81 M | - | - | $ 3.74 B | ||
|
Teva Pharmaceutical Industries Limited
TEVA
|
288 M | $ 28.76 | -3.43 % | $ 32.9 B | ||
|
Enochian Biosciences
ENOB
|
313 K | - | - | $ 40.5 M | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
Equillium
EQ
|
363 K | $ 2.03 | -1.46 % | $ 116 M | ||
|
Eton Pharmaceuticals
ETON
|
65 K | $ 23.81 | 1.51 % | $ 641 M | ||
|
Bellerophon Therapeutics
BLPH
|
203 K | - | -74.18 % | $ 955 K | ||
|
CRISPR Therapeutics AG
CRSP
|
18.6 M | $ 46.38 | -2.45 % | $ 4.17 B |